Study:
Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma
Rationale:
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of tumor cells by blocking blood flow to the tumor. Biological therapies, such as
aldesleukin, may stimulate the immune system in different ways and stop tumor cells from
growing. Giving bevacizumab together with aldesleukin may kill more tumor cells.
Purpose:
This phase II trial is studying how well giving bevacizumab together with
aldesleukin works in treating patients with metastatic clear cell carcinoma of the kidney.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Kidney Cancer |
Biological: aldesleukin
Biological: bevacizumab |
Phase 2 |
Verified by
Case Comprehensive Cancer Center
May, 2012
Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00853021
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Jorge A. Garcia, MD., Principal Investigator